Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 4, 2002, Pages 226-234

  Romero, Alain J ^a,b,c   Le Pogamp, Patrick ^a,b,c   Nilsson, Lars Goran ^a,b,c   Wood, Nolan ^a,b,c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PLACEBO; VORICONAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENTS; PYRIMIDINES; TRIAZOLES;

EID: 0036227007     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121911     Document Type: Article

References (30)

1. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
2. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
3. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
4. The pharmacokinetics and safety of oral voriconazole: A novel broad-spectrum antifungal agent
5. Clinical pharmacokinetics of a new azole - Voriconazole
6. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in man
7. Voriconazole for "salvage" treatment of invasive aspergillosis
8. The efficacy and tolerability of UK 109,496 (voriconazole) in the treatment of invasive aspergillosis (IA)
9. UK109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis - Interim analysis results
10. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
11. Invasive pulmonary aspergillosis refractory to amphotericin B in a patient with persisting neutropenia: Successful treatment with voriconazole
12. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial
13. Cyclosporine: A revolution in transplantation
14. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
15. First-pass metabolism of cyclosporin by the gut
16. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
17. Renal toxicity of long-term cyclosporine
18. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance
19. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pre-clinical pharmacokinetics
20. Prediction of creatinine clearance from serum creatinine
21. A rapid and sensitive HPLC/MS method for the determination of cyclosporine in human blood
22. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column
23. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells
24. Optimisation of itraconazole therapy using target drug concentrations
25. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
26. Unpredictable cyclosporine-fluconazole interaction in renal transplant recipients
27. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients
28. Current and emerging azole antifungal agents